The Egypt Healthcare Authority (EHA), Roche Diagnostics and Roche Pharmaceuticals have signed a memorandum of understanding (MOU) to advance digital pathology in Egypt.

Announced at the fifth Annual Forum on 26 November 2024, this partnership aims to support Egypt's Vision 2030 by enhancing healthcare services through digital transformation and data governance.

The signing ceremony was attended by key executives, including EHA chairman Dr Ahmed El-Sebki and Roche Diagnostics in Egypt and North Africa general manager Dr Leila Kanaan.

Sebki said that the execution of this agreement marks a significant advancement in the swift adoption of modern technology within Egypt's healthcare sector, thereby improving the quality of services available to the citizens.

He emphasised that strengthening collaboration with international partners such as Roche Diagnostics and Roche Pharmaceuticals demonstrates the EHA's dedication to attaining excellence in healthcare services.

Zawya quoted Kanaan as saying in a press release: "At Roche, we are committed to continuing our contribution to the development of healthcare in all our active markets, particularly Egypt, which has made significant progress in recent years, thanks to the country's prioritisation of healthcare issues and the implementation of comprehensive health insurance. 

"We are proud of this strategic collaboration in digital pathology solutions, which will contribute to improving the patient journey across all stages of diagnosis and treatment. In this regard, we will continue to find the best ways to integrate our expertise in healthcare and technology." 

The tripartite partnership is also poised to greatly advance the development of digital pathology methodologies.

It is expected to bolster the EHA's capacity to make informed health decisions utilising the most current global technologies.